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Employing an optimized Pd-catalyzed cross-coupling reaction promoted by CuI, novel N-
ferrocenylpyridazinones along with N-phenyl- and N-(2-pyridyl) analogues were synthetized 
from readily available heterocyclic precursors, iodoferrocene, iodobenzene and 2-
bromopyridine. Except for the ferrocenylation of 6-ferrocenylpyridazin-3(2H)-one yielding both 
N- and O-substituted products, the studied reactions exclusively afforded N-aryl lactams. The 
novel compounds exhibited cytotoxicity on HEPG2 and HT-29 human malignant cells under in 
vitro conditions. The measured IC50 values supplemented with the results of cyclic voltammetry 
and DFT calculations suggest that the cytotoxic activity of the N- and O-ferrocenyl-substituted 
derivatives and the decreased effect of the N-phenyl analogues seem to be at least partly 
associated with the potential to generate reactive oxygen species (ROS). This interpretation, 
allowing to predict characteristic substituent-dependent SAR, was supported by the results of 
related studies on the practically inactive N-(2-pyridyl)pyridazinones assumed to be present in 
protonated chelate forms with highly decreased propensity to undergo ionization. 
2009 Elsevier Ltd. All rights reserved. 
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1. Introduction 
It is a generally accepted view that chemotherapy is one of the 
essential tools for treatment of malignancies. During the last 
decades important advances have been made leading to the 
approval of well-known therapeutic agents, such as cisplatin, 
carboplatin and oxaliplatin
1
 along with a variety of emblematic 
organic compounds which can be represented by eg. 
daunomycin, doxorubicin,
2
 vinblastine and vincristine.
3 
However, 
in order to overcome the frequent toxic limitations and to 
broaden the scope of treatable malignancies, an intense search 
was initiated for alternative therapeutic agents with enhanced 
activity and bioavailability. As a result, besides the afore 
mentioned classical metal complexes and organic molecules, 
organometallics have also emerged as potential anticancer agents. 
Among them ferrocene derivatives with diverse molecular 
architectures are of pronounced importance. It is well 
documented that the replacement of an aromatic nucleus in 
certain organic compounds for a ferrocene unit can lead to 
compounds with enhanced biological activity.
4
 Accordingly, a 
plethora of organic ferrocene derivatives were found to exhibit 
promising antitumor activities.
5
 In most cases their effect is based 
on the generation of radicals through Fenton pathway that causes 
DNA damage and consequent apoptosis of cells.
6
 In this regard, 
capable of playing a highly important role in ROS-production in 
tumorous cells, a variety of N-acyl derivatives of aminoferrocene 
emerged as an intriguing class of cytotoxic agents with 
considerable selectivity toward cancer cells.
7
 It was also 
demonstrated that aminoferrocene-based carbamates can be 
activated by intracellular redox processes which finally increase 
the oxidative stress in cancer cells leading to their death.
8
 On the 
other hand, although the majority of pyridazinone-based 
heterocycles of biological relevance are known for anti-HIV,
9
 
antiviral,
10
 antibacterial,
11
 antihypertensive
12
 and anti-
inflammatory
13
 activities, a number of them have been identified 
as anti-cancer drug candidates,
14
 cyclooxygenase
15
 and PFKFB3 
disphosphatase inhibitors with simultaneous anti-tumouractivity
16
 
showing their promising potential in fighting cancer. Since the 
chemistry and biological applications of ferrocene- and 
pyridazine derivatives are in the focus of our interest, we have 
demonstrated that combination of ferrocene and pyridazinone 
moieties might result in highly promising hybrids exhibiting 
marked antiproliferative activity against human malignant cell 
lines.
17,18
 All of these precedencies prompted us to envisage the 
synthesis and preliminary in vitro evaluation of a small library of 
N-ferrocenylpyridazinones, the cyclic derivatives of N-
acylhydrazinoferrocene, expected to have significant potential in 
ROS-generation associated with antiproliferative activity. 
2. Results and Discussion 
Since the synthesis and characterization of hydrazinoferrocene, a 
reagent with expected enhanced tendency to undergo oxidative 
degradation, have not been reported in the literature so far, we 
envisaged to access the targeted N-ferrocenylpyridazinone 
derivatives through cross-coupling of selected pyridazinone 
components with the easily available iodoferrocene. In order to 
optimize reaction conditions, a series of experiments were carried 
out employing 6-ferrocenylpyridazin-3(2H).one (1)
19
 as substrate 
(Scheme 1). First, we attempted to utilize copper-mediated 
reactions conducted in different solvents using CuI as metal 
source in catalytic or stoichiometric amount (Table 1). It is of 
interest that contrary to the general expectations regarding the 
regioselectivity of Ullmann-Goldberg type amide-N-arylations
20
 
independently on the conditions, the majority of the reactions 
afforded ca. 2:11 mixtures of N- and O-ferrocenyl-substituted 
products 2 and 3, respectively, in low isolated yields. When the 
reactions were performed in dioxane, 2 and 3 could be 
exclusively or partly isolated as DMEDA-coordinated copper 
complexes (Table 1: entries 3 and 5), as indicated by 
1
H-NMR 
measurements. In this series of experiments the coupling reaction 
conducted in DMF containing potassium phosphate and a 
stoichiometric amount of CuI along with DMEDA seemed to be 
the best choice to effect ferrocenylation of 1 (Table 1: entry 9). 
 3 
The simultaneous formation of 2 and 3 is closely related to 
copper(I)-mediated O-arylation of 2-hydroxypyridinesbwith 
sterically demanding aryl halides.
21
 Considering the steric bulk of 
the three-dimensional iodoferrocene, the observed 
regioselectivity is in good agreement with the well-established 
view that Cu-catalyzed C-heteroatom bond-forming reactions are 
strongly influenced by the steric hindrance on the aryl halide 
component.
22 
 
 
Scheme 1 
 
Since the copper-mediated transformations provided low isolated 
yields with a small share of the targeted N-
ferrocenylpyridazinone 2, in the hope of enhancing the efficiency 
and N-selectivity of the model coupling reaction we resorted to 
application of Pd-complexes (PPh3)2PdCl2 and (dppf)PdCl2 as 
single metal source or components in mixed metal systems 
(Table 2). 
The Pd-catalysed reactions carried out in the absence of CuI led 
again to the formation of mixtures of 2 and 3 in low isolated 
yields with ca. 1:8 ratio which proved to be practically invariant 
to the reaction conditions (Table 2: entries 2-4). Changing to a 
Sonogashira type protocol (entry 5), a minimal increase was 
observed in the yield of the regioisomeric products (38%), with a 
doubled ratio of 2 in the isolated mixture. The third series of Pd-
catalyzed reactions carried out in the presence of stoichiometric 
amount of CuI and K2CO3 in DMF:TEA (1:1 v/v) afforded the 
mixture of regioisomeric products in mediocre yields (59-65%: 
entries 7-9) with substantially increased share of 2. It must be 
pointed out here that DMF seems essential to effect the desired 
conversions, as indicated by the fact that no any coupling 
reaction took place when toluene or TEA was used as single 
solvent in the experiments (entries 1 and 6).  
The conditions featuring a satisfactory overall yield (59%) for the 
mixture of 2 and 3 and a reasonable loading (2.5%) of the 
cheaper Pd-catalyst [(PPh3)2PdCl2] (entry 9) was our choice to 
accomplish coupling reactions of condensed pyridazinones 4a-p 
and 6a,b (Scheme 1) equipped with such substituents that might 
enable diversity-oriented synthesis by a variety of further 
functionalizations (4a-h,k-n and 6a,b have been reported,
23
 while 
the procedures affording 4i,j and 4o,p are described in this 
contribution). It is worth to point out that on the bicyclic 
substrates the coupling reactions took place on the sterically 
more accessible lactame nitrogen allowing the exclusive isolation 
of N-ferrocenyl derivatives 5a-p and 7a,b in low-to-mediocre 
yields as presented on Scheme 2. In order to investigate the effect 
of free OH-group in the hydroxyethylamino chain attached to 
phthalazinone scaffold in position 4, a potential donor site in 4h, 
a representative substrate, was protected by simple acetylation 
(4h→4i). This modification increased the efficiency of the 
employed coupling protocol (cf. the isolated yields 16% and 36% 
obtained for conversions 4h→5h and 4i→5i, respectively). On 
the other hand, in the presence of intact 4-(2-hydroxyethyl) chain 
the replacement of the 8-nitro group for phenylthio substituent 
(4h→4j) obviously makes N-ferrocenylation more feasible (cf. 
isolated yield 41% obtained for conversion 4j→5j). It must also 
be pointed out that – probably due to the participation of the 
basic free amino group in the cross-coupling process affording 
highly unstable hydrazinoferrocene type intermediate inclined to 
undergo decomposition – a complex mixture of components 
could be isolated when 4-((2-hydroxyethyl)amino)-8-(1-
methylhydrazinyl)phthalazin-1(2H)-one (4n) was used as 
substrate under the studied conditions. However, its hydrazones 
Table 1: Yields of the mixture of 2 and 3 isolated after the reactions conducted under different conditions employing catalytic or 
stoichiometric amount of CuI 
Entry 
reagent or 
catalyst 
ligand
a
 solvent base T [°C] 
isolated yield 
(%)
b 
1 10% CuI - DMF K2CO3 110 5 
2 10% CuI DMEDA toluene K2CO3 100 0 
3 10% CuI DMEDA dioxane K2CO3 90 (8
c
) 
4 10% CuI DMEDA DMF K2CO3 110 7 
5 100% CuI DMEDA dioxane K2CO3 90 18 (9
c
) 
6 100% CuI DMEDA DMF K2CO3 110 25 
7 100% CuI - TEA K2CO3 80 0 
8 100% CuI DMEDA DMF K2CO3 90 15 
9 100% CuI DMEDA DMF K3PO4 110 33 
10 100% CuI DMEDA DMF KO
t
Bu 110 0 
11 100% CuI TEA DMF K2CO3 80 5 
12 100% CuI DIPA DMF K2CO3 80 3 
13 100% CuI - DMF:TEA 1:1 K2CO3 110 30 
14 100% CuI - DMF:DIPA 1:1 K2CO3 110 16 
a
Performed with 2 eq. of DMEDA or 4 eq. of TEA or 4 eq. of DIPA as ligand. 
b
The product ratio 2:3 was ca. 2:11 as determined by 
1
H-NMR. 
c
Isolated mixture of stoichiometric mono-copper complexes of 2 and 3 as indicated by the CH2- and CH3 signals of DMEDA 
presumably coordinated to the Cu(I)-centre. 
Table 2: Yields of the mixture of 2 and 3 isolated after the reactions conducted under different conditions employing Pd-complexes 
and catalytic or stoichiometric amount of CuI. 
Entry reagent or catalyst solvent base T [°C] isolated yield (%)
 
1 5% (PPh3)2PdCl2 toluene K2CO3 100 0 
2 5% (PPh3)2PdCl2 DMF K2CO3 110 27
a 
3 5% (dppf)PdCl2 DMF K2CO3 110 33
a 
4 5% (PPh3)2PdCl2 DMF:TEA 1:1 K2CO3 110 34
a 
5 
10%. CuI, 
2.5% (PPh3)2PdCl2 
DMF:TEA 1:1 K2CO3 110 38
b
 
6 
100%CuI, 
TEA K2CO3 80 0 
 4 
4o and 4p, obtained by condensations with benzaldehyde and 
formylferrocene, underwent N-ferrocenylation affording 5o and 
5p in low yields (19% and 33%, respectively). The extremely 
low yield of 7a can probably be attributed to the chelation-
induced deactivation of the metal-containing catalyst species by 
the carbonyl-oxygen and the adjacent pyridine nitrogen in 
precursor 6a. In general, the unreacted components were partially 
be recovered from the reaction mixture. 
 
Scheme 2: N-Ferrocenylation of polyfunctional fused 
pyridazinones using reaction conditions presented in entry 9 of 
Table 2 
 
In order to establish structure-activity relationships regarding the 
contribution of the N-aryl group to the cytostatic effect, the 
analogues of representative selection of N-
ferrocenylpyridazinones were also prepared to serve as references 
in the biological assays. Thus, under the conditions employed for 
the ferrocenylation reactions, 1 and 4a were coupled with 
iodobenzene and 2-bromopyridine affording N-phenyl- and N-(2-
pyridyl)pyridazinones (2a/5aa and 2b/5ab, respectively: Scheme 
3), as exclusively isolable products which were not contaminated 
by the corresponding aryloxy-substituted pyridazines. Employing 
iodobenzene as coupling partner phtalazinone 4l was converted 
into 5la serving as a further reference in the in vitro assays, 
however, the reaction conducted under the same conditions in the 
presence of 2-bromopyridine afforded a complex mixture of 
products of which separation has been failed so far. 
 
 
 
Scheme 3: Synthesis of N-arylatedpyridazinones to serve as 
reference organic compounds in the in vitro tests. 
 
The IR- 
1
H- and 
13
C-NMR data of the novel compounds listed in 
the Experimental part are consistent with their structure, only the 
following remarks about the unambiguous discrimination 
between the alternative sites of the amide-arylation reactions are 
necessary to make. The characteristic amide-I band discernible in 
the range 1620-1640 cm
-1
 of the IR spectra of pyridazinones 2, 
5a-p, 7a,b, 2a,b, 5aa, 5ab and 5la refers to their N-arylated 
structure. Accordingly, the C1‘ resonance was identified around 
100 ppm in the 
13
C-NMR spectra registered for 2, 5a-p and 7a,b, 
while in the 
13
C-NMR spectrum of ferrocenyloxypyridazin 3 the 
same signal was detected at 119.9 ppm. The assignment of C1‘-
signal of pronounced diagnostic importance was confirmed by 
comparative GIAO analysis
24
 carried out for the optimized 
structures of 2 and 3, respectively, by B3LYP hybrid functional
25
 
using the extended 6-311++G(2d,p) basis set,
26
 a well-established 
protocol for the calculation of NMR data (the 
measured/calculated shifts: 99.6 ppm/107.2 ppm and 119.9 
ppm/126.2 ppm for 2 and 3, respectively). The optimized 
structures of 2 and 3 were generated by B3PW91 hybrid 
functional
27
 employing DGTZVP basis set.
28
 Note that B3PW91 
has been demonstrated to provide an improvement over B3LYP 
regarding the bonding characterization of metal-containing 
fragments.
29
 
We have studied the cytostatic activity in vitro using human 
HepG2 hepatoma and HT-29 colorectal adenocarcinoma cell 
cultures for a reasonable selection of the novel ferrocene-
containing- and the corresponding organic reference compounds. 
The cells were treated at 10
-4
 to 10
2 
M concentration range and 
the viability of the cells was determined by MTT-assay. The 
activity was characterized by the IC50 values and compared with 
Tamoxifen as positive control. 
The data summarized in Table 3 show that each representative 
compound with N- or O-ferrocenyl substituent produces 
characteristic in vitro cytostatic effect, in average comparable to 
that exhibited by Tamoxifen, on both cell cultures investigated. 
Highlighting the essential contribution of the heteroatom-bonded 
ferrocene unit to cytostatic activity, significantly decreased 
effects could be detected for N-phenylpyridazinones 2a, 5aa and 
5la relative to those measured for their N-ferrocenyl-substituted 
analogues 2, 5a and 5l. These results related to a preliminary 
structure-activity relationship (SAR) suggested that the 
experienced effects might be associated with the production of 
reactive oxygen species (ROS) possibly playing crucial role in 
the observed cytotoxicity.
30
 Accordingly, the compounds 
evaluated in MTT tests were also subjected to comparative cyclic 
voltammetry (CV) affording half-wave potentials E1/2(1) (Table 
3). However, in case of 2, 2a,b, 5g, 5la and Tamoxifen the 
measurements could not be accomplished due to unrevealed 
irreversible reactions producing solid hardly removable 
 5 
undefined coatings on the electrode surface. It is also worth to 
note that two consecutive electron transfers characterized by half-
wave potentials E1/2(1) and E1/2(2) (235.0 mV and 404.5 mV, 
respectively) could be detected only for 3 with spatially separated 
ferrocene redox centers linked to aromatic pyridazine core. 
Nevertheless, taking into account that besides ROS-generation 
the cytotoxic activity of the investigated compounds might also 
be controlled by diverse factors including e.g. bioavailability and 
binding affinity to specific receptors, a satisfactory correlation 
can be established between the relevant E1/2(1) potentials and the 
measured IC50 values. For instance, 5l and 5m, displaying the 
most pronounced cytotoxic effects unambiguously emerged as 
the most efficient reductants in the series of the investigated 
model compounds. On the other hand, since only limited 
experimental data could be collected, and it is reasonable to 
assume that the measured half-wave potentials (particularly 
E1/2(2) obtained for 3) are also affected by solvation, diffusion (a 
non-thermodynamic effect), ionic strength, chemical and physical 
interactions with the electrode surface and – under the employed 
experimental conditions – an enhanced degree of coordination of 
the solvent acetonitrile molecules with highly structure-
dependent modes to the cationic species
31
, we undertook 
complementary DFT studies on the redox properties of the tested 
compounds at B3PW91 level of theory using DGTZVP basis set 
on the neutral compounds and the corresponding radical cationic 
species with doublet electron configuration generated by 
removing one electron from the HOMO of the parent molecules. 
The first adiabatic ionization energy [Ei(1)] values
32
,
 
presumably 
relevant under biological conditions were obtained as the 
difference in the total electron energy values calculated for the 
optimized structures of the analyzed compounds and the 
appropriate radical cationic species, respectively. Supporting our 
view regarding the above-discussed cytotoxic activity, at least 
particularly associated with ROS-generation, the measured 
E1/2(1) potentials, the calculated HOMO levels and Ei(1) values 
(Table 3) seem to be in acceptable correlation with the IC50 data 
derived from in vitro assay. For instance, N-
ferrocenylpyridazinones 2 and 5l with higher HOMO levels 
undergo ionization more readily [EHOMO(1)/Ei(1)= -5.47 eV/6.15 
eV and = -5.12 eV/5.64 eV, resp.] than their N-phenyl-substituted 
counterparts 2a and 5la [EHOMO(1)/Ei(1)= -5.80 eV/7.21 eV and -
5.37 eV/6.34 eV, resp.]. However, it must be commented that 
N-(2-pyridyl)pyridazinone 2b exhibiting no detectable effect in 
the test can be characterized by somewhat higher HOMO-level 
and lower ionization energy [EHOMO(1)= -5.73 eV and Ei(1)=7.02 
eV] than its N-phenyl-substituted counterpart 2a [EHOMO(1)= -
5.80 eV and Ei(1)=7.21 eV]. This finding can be explained by the 
facile alternative chelate-forming modes of protonation of 2b 
probably taking place under biological conditions to afford 
cationic pair 2bH1
+
 and 2bH2
+
 (Scheme 4) of which DFT 
analysis revealed their relative stability and highly decreased 
propensity to undergo ionization probably associated with ROS-
generation [cf. enhanced HOMO levels and Ei(A) data in Table 
3.]. According to the relative energetics 2bH2
+
 stabilized by six-
membered chelate ring is expected to be overpopulated relative to 
its isomeric pair 2bH1
+
 with five-membered chelate residue. It 
must be noted here that contrary to N-ferrocenylphthalazinone 5a 
with relatively high EHOMO(1) level (-5.46 eV) and somewhat 
increased first adiabatic ionization energy (Ei(1)=6.42 eV) 
enabling to exert remarkable activity against both cell lines 
investigated, neither N-phenyl-substituted analogue 5aa nor N-
(2-pyridyl)phthalazinone 5ab with substantially lowered 
EHOMO(1) levels (-6.34 eV and -6.54 eV, respectively) and 
increased Ei(1) (-7.98 eV and -7.74 eV, respectively) values 
proved to be practically inactive in the in vitro tests. Moreover, 
5ab is also expected to readily bind proton in alternative chelated 
fashions to afford expectably highly deactivated cations 5abH1
+
 
and 5abH2
+
 [cf. lowered EHOMO(1) and enhanced Ei(1) values in 
Table 3] with a dominance of the latter one as suggested by their 
calculated relative energetics (Scheme 4). 
 
 
Scheme 4: Relative energy values calculated for isomeric pairs of 
protonated N-(2-pyridyl)pyridazinones, the species assumed to be 
present under biological conditions, with high ionization energy 
associated with significantly decreased tendency to generate 
ROS. 
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In order to obtain additional information about the structural 
characteristics that might provide plausible interpretation for 
redox properties of the prepared compounds and, in particular, 
for the unique propensity of ferrocenyloxypyridazin 3 to undergo 
sequentional SET processes under the CV conditions employed, 
a reasonable selection of diamagnetic dications were also 
modelled by B3PW91/DGTZVP method (Table 3). However, the 
second adiabatic ionization energy values [Ei(2)] obtained as the 
relative energetics of the optimized structures of dications and the 
appropriate radical cations (Table 3) do not suggest an 
outstanding propensity of 3
+
 to undergo oxidation. This apparent 
contradiction might be attributed to an enhanced degree of 
coordination of the solvent acetonitrile molecules to the cationic- 
and particularly to dicationic species
31
 which interaction was not 
taken into account for theoretical studies as a highly demanding 
uncertain explicit solvent model.  Nevertheless, we attempted to 
support this concept by a highly preliminar theoretical study on 
acetonitrile-promoted stepwise ionization of 5a, a characteristic 
representative of the studied compounds with reasonable 
structural complexity (Scheme 5). The modified ionization 
energies Ei(1)* and Ei(2)* unambiguosly referring to solvent-
promoted SET processes were obtained as the appropriate 
differences of the energetics of the optimized structures of non-
coordinated 5a and cationic mono-acetonitrile complexes 5a
+
.L 
and 5a
2+
.L featuring slightly and substantially distorted 
metallocene structure with negligible and strong Fe-N 
interactions (interatomic distances: 4.547 Å and 1.944 Å, 
respectively). Selected bonding interactions inside the modeled 
acetonitrile complexes are visualized by representative delocalized 
MO’s with energy levels referring to a much stronger coordination 
of the ligand in dication 5a2+.L than in radical cation 5a+.L (Scheme 
5). 
The method used (B3PW91/DGTZVP) could not disclose any 
interaction between 5a and MeCN. 
 
 
 
 
Table 3. In vitro cytostatic effects on two human malignant cell lines expressed as IC50 values, measured for the selected compounds 
and Tamoxifen (serving as reference) along with experimental [E1/2(1)
a
 and E1/2(2)
b
] and theoretical parameters [EHOMO(1)
c
 / EHOMO(2)
d
 
and Ei(1)
e
 / Ei(2)
f
]
g
 characterizing their redox properties of potential relevance in ROS-generation, one of the possible mechanisms 
responsible for the observed antiproliferative effects. 
 
Compound 
IC50± SD [µM]  
E1/2(1) 
[mV]
a
 
 
E1/2(2) 
[mV]
b
 
 
EHOMO(1) 
[eV]
c,g
 
 
EHOMO(2) 
[eV]
d,g
 
 
Ei(1) 
[eV]
e,g
 
 
Ei(2) 
[eV]
f,g
 
HepG2 HT-29 
2 19.6 ± 2.4 11.0 ± 3.2 - - -5.47 -8.16 6.15 10.79 
2a 43.8 ± 2.0 41.7 ± 3.5 - - -5.80 -9.20 7.21 10.72 
2b >100 >100 - - -5.73 -9.38 7.02 11.00 
[2bH1
+
]
h
 - - - - -8.61 - 9.89 - 
[2bH2
+
]
h
 - - - - -8.47 - 9.86 - 
3 19.6 ± 0.5 18.6 ± 7.9 235.0 404.5 -5.43 -7.84 6.10 10.74 
5a 16.4 ± 0.5 20.7 ± 7.0 239.5 - -5.46 -8.22 6.91 11.16 
5aa >100 >100 - - -6.34 -10.76 7.74 12.16 
5ab >100 >100 265.5 - -6.54 -10.94 7.97 12.34 
[5abH1
+
]
h
 - - - - -10.47 - 11.90 - 
[5abH2
+
]
h
 - - - - -10.54 - 11.53 - 
5b 16.5 ± 4.3 25.2 ± 5.0 256.5 - -5.35 -8.93 6.03 10.74 
5g 19.9 ± 10.0 54.8 ± 11.1 - - -5.40 -9.53 6.05 11.44 
5l 5.7 ± 0.1 9.8 ± 1.2 168.0 - -5.12 -8.09 5.64 10.03 
5la 79.8 ± 18.9 27.1 ± 8.0 - - -5.39 -8.56 6.34 10.01 
5m 11.3 ± 4.0 15.5 ± 5.4 172.5 - -5.16 -8.33 5.84 10.18 
7b 24.1 ± 23.2 35.9 ± 7.5 207.0 - -5.45 -9.15 6.09 11.05 
[7bH
+
]
h
 - - - - -8.10 - 8.46 - 
Tamoxifen 20.0 ± 6.5 15.6 ± 5.7 - - -5.55 -8.39 6.51 9.77 
a
 First half-wave potential obtained in CV-measurements. 
b
 Second half-wave potential obtained in CV-measurements. 
c
 HOMO level of the parent compounds and the presented protonated forms. 
d
 HOMO level of the corresponding radical cations.  
e
 Adiabatic ionization energy of the parent compounds and the presented protonated forms 
f
 Adiabatic ionization energy of the corresponding radical cations. 
g
 Resulted from B3PW91/DGTZVP calculations. 
h
 Assumed to be at least partially present under the conditions of in vitro assays. 
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Scheme 5. DFT-modelled stepwise oxidations of 5a taking place in the absence and in the presence of 1 equivalent of 
acetonitrile as represented by the optimized structures of the parent molecule and the resulting non-coordinated and 
coordinated cationic intermediates supplemented with representative bonding MO’s identified for cationic complexes. The 
calculated ionization energies refer to the promoter role of the solvent stabilizing the resulting cations. 
 
 
Figure 1. Optimized structures and relevant high-energy 
occupied MO’s of selected pyridazine-based products and 
Tamoxifen along with their appropriate radical cations. 
 
Besides relative ionization energies HOMO levels of the radical 
cations can also be considered as the measure of their propensity 
to undergo ionization affording dicationes. Thus, in accord with 
the experimental findings, radical cation 3
+
 features a HOMO 
lying substantially higher in energy [EHOMO(2)=-7.84 eV] than the 
HOMO’s of other studied radical cations with N-ferrocenyl/aryl s 
keleton [note as characteristic examples: EHOMO(2)=-8.16 eV for 
2
+
, -8.09 eV for 5l
+
 and -8.33 eV for 5m
+
]. 
As indicated by the delocalization of the HOMO’s of the 
selection of the modelled products (Figure 1), compound 3 
undergoes an O-ferrocenyl-centered primary SET, while 
substantially extended parts of the whole molecular skeletons are 
involved in the first ionization of N-ferrocenyl/arylpyridazinones. 
The delocalization of the HOMO of radical cation 3
+
 indicates 
that the second electron transfer detectable in CV experiments 
carried out with 3 is centered on the C-ferrocenyl group. 
Moreover, in this radical cation the HOMO-1 and HOMO-2, with 
energy levels higher to those identified for the isomeric radical 
cation 2
+
, are also concentrated on the same metallocene 
fragment assumably also increasing the chance of the second 
ionization. 
In this context the redox chemistry of reference Tamoxifen must 
also be commented on. Recent CV studies conducted under non-
aqueous conditions disclosed that its irreversible primary 
oxidation generates a very short-lived amine radical cation which 
readily abstracts a H-atom from the solvent or an adventitious 
reactant finally affording the corresponding ammonium ion.
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This finding is in accord with the mainly amine-centered HOMO 
we identified for the radical cation generated from Tamoxifen 
(Figure 1). On the other hand, the reletively high-energy HOMO 
of Tamoxifen is delocalized over the whole phenylstyrene 
skeleton with slight extension toward the basic side-chain. 
Besides the obvious electronic- and chelate-forming properties of 
the N/O-ferrocenyl/aryl group, the relative tendency of the tested 
fused pyridazinones type 5 to undergo ionization is spectacularly 
controlled by the electronic effects of the substituents bonded in 
positions 4 and 8 which can significantly contribute to the 
stabilization of the radical cationic species, as clearly indicated 
by the markedly increased cytotoxic activity of 5l relative to that 
of 5a. The HOMO-raising activation of 5l to behave as a 
potential reductant can be ascribed to the donor-type C-
substituents significantly contributing to the stabilization of 
ground-state 5l
+
, as spectacularly represented by HOMO, 
 8 
HOMO-1 and HOMO-2 with pronounced delocalization 
involving the side chains. This view gains support from 
oxidation-induced shortening of the C4-N and C8-N bond lengths 
discernible in the optimized structures of this redox pair (C4-
N/C8-N: 1.381 Å/1.358 Å and 1.361 Å/1.350 Å in 5l and 5l
+
, 
respectively) pointing to intensified lone-pair delocalization from 
the directly attached nitrogen atoms towards the heterocyclic 
skeleton in 5l
+
.  
The important contribution of the amine-based side-chains to the 
ROS-induced cytotoxic effect is spectacularly reflected from the 
comparison of IC50-, EHOMO(1)- and Ei(1) values found for 
inactive 5aa and active 5la, respectively (Table 3). It is also 
worth to pay attention to the IC50-, E1/2(1)-, EHOMO(1)- and Ei(1) 
values obtained for 5l and 5m with an almost negligible 
structural difference in the terminal region of their C8-
substituents. The lowered cytotoxic activity of 5m relative to that 
of 5l, assumed at least partly associated with slightly decreased 
level of ROS-generation, might be the consequence of the 
decreased basicity of the hydroxyl group in 5m relative to that of 
the piperidinyl group in 5l which is involved in a five-membered 
chelate ring of a bifurcated H-bond system (with the carbonyl-
oxygen as the second donor site), capable of strengthening the 
abovementioned lone pair delocalization from the directly 
attached nitrogen towards the electron-deficient heterocyclic 
skeleton in 5l
+
. This view gains support from the spectacularly 
different extensions and energies of the two highest-level 
occupied orbitals (HOMO and HOMO-1) visualized for 5l
+
 and 
5m
+
, respectively, consistent with the small but definite 
difference in the C8-N bond lengths found in their optimized 
structures (1.349 Å and 1.353 Å in 5l
+
 and 5m
+
, respectively). 
Accordingly, the same C4-N atomic distance (1.361 Å) is 
discernible in both of these cations carrying 2-
hydroxyethylamino group in position 4. 
3. Conclusions 
Starting from easily available pyridazinone-based precursors and 
iodoferrocene a Cu-mediated cross-coupling protocol employing 
Pd-catalysis provided 3-ferrocenyl-6-ferrocenyloxypyridazine 
and a series of novel N-ferrocenyl-substituted lactams, the first 
representatives of novel classes of functionalized organometallics 
with promising antitumor actions at micromolar concentrations 
on HepG2 and HT-29 tumor cell cultures. The use of a diversity 
of further pyridazinones and related lactams is expected to result 
in a library of related ferrocene-containing cytostatic heterocycles 
of which activity seems to be – at least partly – associated with 
ROS-generation. This view was supported by the well-correlated 
results of comparative biological tests, cyclic voltammetry (CV) 
experiments and DFT studies carried out on selected 
organometallic derivatives and on their N-phenyl- and N-(2-
pyridyl)-substituted analogues. Besides the feasibility of further 
coupling reactions including conjugation to biomolecules enabled 
by the functional groups attached to the heterocyclic scaffolds the 
established structure-activity relationships, disclosing the 
importance of highly substituent-dependent fine-tunable redox 
properties, might be taken into account for a rational fragment-
based design of related organometallic- and purely organic drug 
candidates. 
4. Experimental section 
All chemicals (expect iodoferrocene, which was prepared 
according to the method of Fish and Rosenblum
34
) were obtained 
from commercially available sources (Aldrich, Fluka) and used 
without further purification, expect solvents. Methanol, dioxane 
and triethylamine (TEA) were distilled from sodium, N,N-
dimethylformamide was distilled from 4A Molecular sieves 
under reduced pressure. Melting points (uncorrected) were 
determined with a Boethius microstage. Merck Kieselgel (230-
400 mesh, 60 Å) was used for flash column chromatography. The 
IR spectra were run by ATR (Attenuated Total Reflectance) 
method on a Bruker IFS-55 FT-spectrometer controlled by Opus 
3.0 software. The exact mass measurements were performed 
using a Q-TOF Premier mass spectrometer (Waters Corporation, 
34 Maple St, Milford, MA, USA) in positive electrospray mode. 
The 
1
H and 
13
C NMR spectra were recorded in DMSO-d6 or 
CDCl3 solution in 5 mm tubes at RT, on a Bruker DRX-500 
spectrometer at 500 (
1
H) and 125 (
13
C) MHz, with the deuterium 
signal of the solvent as the lock and TMS as internal standard 
(
1
H, 
13
C). The 2D-COSY, HSQC and HMBC spectra were 
obtained by using the standard Bruker pulse programs. 
Optimized structures are available from the authors. 
 
Preparation of 4-((2-acetoxyethyl)amino)-8-nitrophthalazin-
1(2H)-one (4i) from 4h 
 
Phthalazinone 4h (2.50 g, 10mmol) was dissolved in glacial 
acetic acid (20 mL) and the solution was refluxed for 2 h. The red 
colored reaction mixture was concentrated in vacuum to half of 
its volume then diluted with water. The precipitated solid was 
filtered off and recrystallized from water (ca. 130-150 mL). 
Yellow solid; Yield: 2.12 g (73%); mp.: 231.1-232.6 °C (from 
H2O); IR (ATR, cm
-1
): 3385, 3352, 1748, 1730, 1658, 1589, 
1529, 1455, 1431, 1372, 1339, 1309, 1248, 1233, 1219, 1179, 
1154, 1139, 1032, 981, 951, 851, 822, 746, 712, 663, 605, 574, 
387, 370; 
1
H-NMR (DMSO-d6): 11.95 (1H, s, H2), 8.31 (1H, dd, 
J = 6.5 Hz, 2.9 Hz, H5), 8.08 (1H, d, J = 7.7 Hz, H7, overlapped 
by H6), 8.07 (1H, t, J = 7.6 Hz, H6, overlapped by H7), 6.98 (1H, 
t, J = 5.4 Hz, CH2NH), 4.21 (2H, t, J = 5.8 Hz, CH2O), 3.48 (2H, 
q, J = 5.7 Hz, CH2NH), 1.99 (3H, s, COCH3); 
13
C-NMR (DMSO-
d6): 171.0 (COCH3), 154.6 (C1), 149.2 (C8), 144.3 (C4), 134.5 
(C6), 126.7 (C4a), 126.2 (C5), 125.7 (C7), 119.0 (C8), 62.3 
(CH2O), 40.6 (CH2NH). HRMS exact mass calcd. for 
C12H13N4O5 [MH]
+
, requires m/z 293.0886, found m/z 293.0879. 
 
Preparation of 4-((2-hydroxyethyl)amino)-8-
(phenylthio)phthalazin-1(2H)-one (4j) from 4h 
 
Phthalazinone 4h (2.50 g, 10 mmol), thiophenol (1.32 g, 12 
mmol) and K2CO3 (2.21 g, 1.6 mmol) were dissolved in DMF (15 
mL) and the solution was refluxed for 5 h. The yellow reaction 
mixture was diluted with water and the precipitated solid was 
filtered off and recrystallized from EtOH (ca. 80-100 mL). 
White solid; Yield: 1.92 g (61%) ; mp.: 307.4-310.7 °C (from 
EtOH); IR (ATR, cm
-1
): 3330, 2997, 2863, 1625, 1578, 1534, 
1509, 1460, 1438, 1333, 1320, 1229, 1175, 1136, 1068, 1022, 
998, 915, 810, 779, 757, 705, 693, 666, 606, 540, 476, 428, 415, 
401, 362; 
1
H-NMR (DMSO-d6): 11.61 (1H, s, H2), 7.73 (1H, d, J 
= 8.0 Hz, H5), 7.58-7.51 (6H, m, H6 and H2”-H6”), 6.76 (1H, d, 
J = 8.0 Hz, H7), 6.45 (1H, t, J = 5.3 Hz, CH2NH), 4.69 (1H, t, J = 
5.5 Hz, CH2OH), 3.59 (2H, q, J = 5.8 Hz, CH2OH), 3.29 (2H, q, 
J = 5.8 Hz, CH2NH); 
13
C-NMR (DMSO-d6): 159.8 (C1), 145.2 
(C4), 144.0 (C8), 136.4 (C3” and C5”), 132.8 (C6), 132.4 (C1”), 
130.8 (C2” and C6”), 130.2 (C4”), 127.4 (C7), 127.0 (C4a), 
123.5 (C8a), 59.1 (CH2OH), 44.6 (CH2NH). HRMS exact mass 
calcd. for C16H16N3O2S [MH]
+
, requires m/z 314.0963, found m/z 
314.0970. 
 
Preparation of imines 4o and 4p from 4-((2-
hydroxyethyl)amino)-8-(1-methylhydrazinyl)phthalazin-1(2H)-
one (4n) 
 
 9 
Benzaldehyde (0.531 g, 5 mmol) or formylferrocene (1.070 g, 5 
mmol) in MeOH (1 mL) was added to 4n (1.250 g, 5 mmol) 
suspended in MeOH (5 mL) and the resulting suspension was 
stirred at 65 °C for 12 h. The reaction mixture was cooled down 
to room temperature, and the solid precipitate formed was filtered 
off washed with water and dried over P2O5 in vacuum. 
 
(E)-8-(2-benzylidene-1-methylhydrazinyl)-4-((2-
hydroxyethyl)amino)phthalazin-1(2H)-one (4o) 
Light yellow solid; Yield: 1.459 g (86%); mp.: 274.2-276.9 °C 
(from MeOH); IR (ATR, cm
-1
): 3266, 1628, 1589, 1562, 1533, 
1477, 1445, 1418, 1393, 1377, 1309, 1291, 1252, 1200, 1162, 
1130, 1100, 1089, 1067, 995, 922, 882, 873, 853, 821, 811, 790, 
769, 757, 700, 691, 674, 653, 615, 581, 552, 520, 460; 
1
H-NMR 
(DMSO-d6): 11.31 (1H, s, CONH), 7.78 (1H, t, J = 7.8 Hz, H6), 
7.76 (1H, d, J = 7.5 Hz, H5), 7.72 (1H, dd, J = 7.0 Hz, 2.0 Hz, 
H7), 7.68 (1H, s, CHPh), 7.67 (2H, d, J = 7.7 Hz, H2’ and H6’), 
7.38 (2H, t, J = 7.6 Hz, H3’ and H5’), 7.27 (1H, t, J = 7.3 Hz, 
H4’), 6.33 (1H, t, J = 5.4 Hz, NH), 4.66 (1H, t, J = 5.7 Hz, OH), 
3.64 (2H, q, J = 6.0 Hz, CH2OH), 3.33 (2H, q, J = 5.8 Hz, 
CH2NH, overlapped by HDO signal of the solvent), 3.28 (3H, s, 
CH3); 
13
C-NMR (DMSO-d6): 157.0 (C1), 149.6 (C8), 145.2 (C4), 
137.0 (C1’), 134.2 (CHPh), 132.9 (C6), 129.0 (C3’ and C5’), 
128.0 (C4’), 127.8 (C4a), 126.2 (C7 and C2’ and C6’), 119.2 
(C5), 118.2 (C8a), 59.8 (CH2OH), 44.7 (CH2NH), 42.2 (CH3). 
HRMS exact mass calcd. for C18H20N5O2 [MH]
+
, requires m/z 
293.0886, found m/z 293.0892. 
 
(E)-8-(2-ferrocenylidene-1-methylhydrazinyl)-4-((2-
hydroxyethyl)amino)phthalazin-1(2H)-one (4p) 
Reddish orange solid; Yield: 1.93 g (87%); mp.: 235.2-238.6 
(degr.) °C (from MeOH); IR (ATR, cm
-1
): 3210, 1618, 1582, 
1540, 1466, 1387, 1293, 1249, 1215, 1177, 1154, 1124, 1104, 
1050, 1039, 990, 939, 875, 850, 822, 801, 765, 703, 682, 644, 
621, 569, 520, 493, 482, 450, 440, 419; 
1
H-NMR (DMSO-d6): 
11.29 (1H, s, CONH), 7.77 (1H, t, J = 7.9 Hz, H6), 7.70 (1H, d, J 
= 7.9 Hz, H5), 7.67 (1H, d, J = 7.9 Hz, H7), 7.49 (1H, s, FcCH), 
6.34 (1H, t, J = 5.2 Hz, NH), 4.70 (1H, t, J = 5.4 Hz, OH), 4.62 
(2H, br s, H2’ and H5’), 4.33 (2H, br s, H3’ and H4’), 4.19 (5H, 
s, η
5
-C5H5), 3.63 (2H, q, J = 5.3 Hz, CH2OH), 3.33 (2H, q, J = 
5.3 Hz, CH2NH), 3.18 (3H, s, CH3); 
13
C-NMR (DMSO-d6): 157.0 
(C1), 150.0 (C8), 145.2 (C4), 133.0 (C6), 127.8 (C4a), 125.3 
(C7), 118.5 (C8a), 117.3 (C5), 134.7 (FcCH), 83.0 (C1’), 69.4 
(η
5
-C5H5), 69.3 (C3’ and C4’), 66.9 (C2’ and C5’), 59.8 
(CH2OH), 44.6 (CH2NH), 42.4 (CH3). HRMS exact mass calcd. 
for C22H24N5O2
56
Fe [MH]
+
, requires m/z 446.1279, found m/z 
446.1282. 
 
General method for the coupling reactions of pyrydazin-based 
lactams with aryl halides iodoferrocene, iodobenzene and 2-
bromopyridine 
 
The precursor lactam (1 mmol) was dissolved in DMF-TEA 1:1 
(2 mL) ,then K2CO3 (0.410 g, 3 mmol), CuI (190 mg, 1 mmol), 
PdCl2(PPh3)2 (17.5 mg, 0.025 mmol) and aryl halide (1.1 mmol) 
were added to the solution. The reaction mixture was stirred 
under argon, at 110 °C for overnight. The reaction mixture was 
filtered and brine (30 mL) was added to the solution. The 
precipitated solid was filtered off then washed with brine and 
water. The crude product was purified by column 
chromatography (on silica, using DCM or DCM-MeOH 100-5:1 
mixtures as eluent) and subsequent crystallization from MeOH, 
EtOH, 
i
PrOH, 
t
BuOH, MeOH-water or EtOH-water. 
 
2,6-diferrocenylpyridazin-3(2H)-one (2) 
Red solid, Yield: 72.1 mg (16%); mp.: 197.3-199.2 °C (from 
EtOH); IR (ATR, cm
-1
): 3095, 1654, 1597, 1551, 1488, 1411, 
1394, 1368, 1304, 1270, 1230, 1120, 1105, 1078, 1058, 1026, 
1000, 932, 890, 843, 817, 676, 579, 545, 503, 484, 443, 391, 381; 
1
H-NMR (DMSO-d6): 7.74 (1H, d, J = 9.6 Hz, H5), 6.94 (1H, d, 
J = 9.6 Hz, H4), 5.16 (2H, s, H2’ and H5’), 4.97 (2H, t, J = 1.8 
Hz, H2’’ and H5’’), 4.52 (2H, t, J = 1.8 Hz, H3’’ and H4’’), 4.26 
(2H, s, H3’ and H4’), 4.21 (5H, s, 2-η
5
-C5H5), 4.18 (5H, s, 6-η
5
-
C5H5); 
13
C-NMR (DMSO-d6): 158.8 (C3), 146.3 (C6), 130.9 
(C5), 129.7 (C4), 99.6 (C1’), 80.4 (C1’’), 70.9 (C3’’ and C4’’), 
70.0 (2-η
5
-C5H5 and 6-η
5
-C5H5), 67.3 (C2’’ and C5’’), 66.3 (C3’ 
and C4’), 64.4 (C2’ and C5’). HRMS exact mass calcd. for 
C24H21N2O
56
Fe2 [MH]
+
, requires m/z 465.0353, found m/z 
465.0345. 
 
3-ferrocenyl-6-ferrocenyloxypyridazine (3) 
Dark red solid, Yield: 201.9 mg (43%); mp.: 185.4-186.7 °C 
(from EtOH); IR (ATR, cm
-1
): 1660, 1592, 1522, 1457, 1392, 
1302, 1282, 1236, 1219, 1173, 1130, 1104, 1096, 1070, 1026, 
998, 916, 882, 849, 820, 801, 687, 625, 503, 483, 454, 440, 398; 
1
H-NMR (DMSO-d6): 7.92 (1H, d, J = 9.2 Hz, H4), 7.29 (1H, d, 
J = 9.2 Hz, H5), 5.03 (2H, t, J = 1.8 Hz, H2’ and H5’), 4.56 (2H, 
s, H2’’ and H5’’), 4.49 (2H, t, J = 1.8 Hz, H3’’ and H4’’), 4.27 
(5H, s, 6-η
5
-C5H5), 4.07 (7H, s, H3’’ and H4’’ and 3-η
5
-C5H5); 
13
C-NMR (DMSO-d6): 165.0 (C6), 158.3 (C3), 128.8 (C4), 119.9 
(C1’), 117.7 (C5), 80.9 (C1’’), 70.8 (C3’ and C4’), 70.0 (3-η
5
-
C5H5), 69.7 (6-η
5
-C5H5), 67.7 (C2’ and C5’), 63.6 (C3’’ and 
C4’’), 61.7 (C2’’ and C5’’). HRMS exact mass calcd. for 
C24H21N2O
56
Fe2 [MH]
+
, requires m/z 465.0353, found m/z 
465.0348. 
 
2-ferrocenylphtalazin-1(2H)-one (5a) 
Reddish orange solid; Yield: 73.0 mg (22%); mp.: 133.6-135.8 
°C (from EtOH); IR (ATR, cm
-1
): 1656, 1593, 1483, 1458, 1449, 
1399, 1360, 1344, 1324, 1309, 1275, 1240, 1227, 1157, 1134, 
1117, 1102, 1080, 1034, 1024, 1014, 996, 966, 929, 907, 989, 
979, 844, 834, 815, 805, 763, 726, 686, 598, 537, 503; 
1
H-NMR 
(DMSO-d6): 8.57 (1H, br s, H4), 8.33 (1H, d, J = 7.9 Hz, H8), 
7.97 (1H, d, J = 7.9 Hz, H5, overlapped by H5), 7.96 (1H, td, J = 
7.9 Hz, 1.3 Hz, H6, overlapped by H6), 7.90 (1H, td, J = 7.9 Hz, 
1.8 Hz, H7), 5.13 (2H, t, J = 2.0 Hz, H2’ and H5’), 4.24 (2H, t, J 
= 2.0 Hz, H3’ and H4’), 4.16 (5H, s, η
5
-C5H5); 
13
C-NMR 
(DMSO-d6): 158.4 (C1), 139.2 (C4), 134.1 (C6), 133.0 (C7), 
129.1 (C4a), 128.2 (C8a), 127.6 (C5), 126.6 (C8), 100.3 (C1’), 
69.8 (η
5
-C5H5), 66.0 (C3’ and C4’), 64.0 (C2’ and C5’). HRMS 
exact mass calcd. for C18H15N2O
56
Fe [MH]
+
, requires m/z 
331.0534, found m/z 331.0540. 
 
4-(diethylamino)-2-ferrocenylphthalazin-1(2H)-one (5b) 
Orange solid; Yield: 137.3 mg (34%); mp.: 131.5-132.5 °C (from 
EtOH); IR (ATR, cm
-1
): 2973, 1656, 1584, 1551, 1484, 1464, 
1448, 1407, 1397, 1382, 1370, 1331, 1316, 1290, 1234, 1204, 
1171, 1140, 1117, 1105, 1085, 1074, 1062, 1021, 999, 967, 888, 
856, 827, 809, 780, 745, 719, 695, 678, 600, 555, 502, 492, 461, 
429, 401; 
1
H-NMR (DMSO-d6): 8.33 (1H, br d, J = 7.8 Hz, H8), 
7.98-7.92 (2H, m, H5 and H6), 7.87 (1H, ddd, J = 7.8 Hz, 6.5 Hz, 
1.9 Hz, H7), 5.14 (2H, t, J = 1.9 Hz, H2’ and H5’), 4.21 (2H, t, J 
= 1.9 Hz, H3’ and H4’), 4.14 (5H, s, η
5
-C5H5), 3.32 (4H, q, J = 
7.0 Hz, NCH2), 1.19 (6H, t, J = 7.0 Hz, CH3); 
13
C-NMR (DMSO-
d6): 157.4 (C1), 147.9 (C4), 133.6 (C6), 132.2 (C7), 129.2 (C8a), 
127.4 (C8), 126.8 (C4a), 125.4 (C5), 100.3 (C1’), 69.6 (η
5
-C5H5), 
65.7 (C3’ and C4’), 63.6 (C2’ and C5’), 45.6 (NCH2), 12.6 
(CH3). HRMS exact mass calcd. for C22H24N3O
56
Fe [MH]
+
, 
requires m/z 402.1269, found m/z 402.1260. 
 
2-ferrocenyl-4-(pyrrolidin-1-yl)phtalazin-1(2H)-one (5c) 
 10 
Orange solid; Yield: 107.6 mg (27%); mp: 140.2-142.5 °C (from 
EtOH); IR (ATR, cm
-1
): 2960, 2930, 2861, 1641, 1609, 1575, 
1526, 1492, 1466, 1438, 1407, 1363, 1330, 1241, 1231, 1161, 
1148, 1104, 1076, 1030, 1019, 997, 949, 928, 912, 893, 856, 817, 
788, 778, 756, 718, 686, 655, 643, 628, 615, 595, 535, 498, 485, 
459, 446, 408; 
1
H-NMR (DMSO-d6): 8.34 (1H, dd, J = 7.8 Hz, 
1.5 Hz, H8), 8.15 (1H, d, J = 8.0 Hz, H5), 7.91 (1H, td, J = 7.6 
Hz, 1.5 Hz, H6), 7.85 (1H, td, J = 7.5 Hz, 1.2 Hz, H7), 5.13 (2H, 
t, J = 2.0 Hz, H2’ and H5’), 4.18 (2H, t, J = 2.0 Hz, H3’ and 
H4’), 4.14 (5H, s, η
5
-C5H5), 3.61 (4H, t, J = 6.5 Hz, H2’’ and 
H5’’), 1.96 (4H, tt, J = 6.5 Hz, 2.0 Hz, H3’’and H4’’); 
13
C-NMR 
(DMSO-d6): 157.0 (C1), 147.2 (C4), 133.2 (C6), 132.0 (C7), 
129.2 (C8a), 127.7 (C8), 126.1 (C4a), 125.9, (C5), 69.7 (η
5
-
C5H5), 65.5 (C3’ and C4’), 63.6 (C2’ and C5’), 51.0 (C2’’ and 
C5’’), 25.5 (C3’’ and C4’’). HRMS exact mass calcd. for 
C22H24N3O
56
Fe [MH]
+
, requires m/z 400.1112, found m/z 
400.1107.  
 
4-(2,6-dimethylmorpholino)-2-ferrocenylphthalazin-1(2H)-one 
(5d) 
Yellowish orange solid; Yield: 100.0 mg (23%); mp.: 160.6-
162.8 °C (from EtOH); IR (ATR, cm
-1
): 2977, 2853, 1656, 1587, 
1547, 1487, 1468, 1452, 1422, 1398, 1379, 1363, 1329, 1317, 
1269, 1234, 1123, 1187, 1174, 1144, 1104, 1084, 1072, 1054, 
1038, 1024, 1000, 968, 930, 895, 860, 817, 790, 778, 767, 724, 
698, 678, 658, 648, 599, 503, 489, 462, 428, 406; 
1
H-NMR 
(CDCl3): 8.45 (1H, br s, H8), 7.88 (1H, br d, J = 4.1 Hz, H5), 
7.80 (1H, br s, H6), 7.76 (1H, br s, H7), 5.46 (2H, s, H2’ and 
H5’), 4.45 (2H, s, H3’ and H4’), 4.41 (5H, s, η
5
-C5H5), 4.04 (2H, 
br s, CHCH3O), 3.44 (2H, br d, J = 8.2 Hz, H3’’a and H5’’a), 
2.79 (2H, br t, H3’’b and H5’’b), 1.31 (6H, s, CH3, overlapped by 
HDO signal of the solvent); 
13
C-NMR (CDCl3): 157.8 (C1), 
148.3 (C4), 132.5 (C6), 131.4 (C7), 129.6 (C4a), 127.8 (C8), 
125.6 (C8a), 124.5 (C5), 71.7 (η
5
-C5H5), 71.6 (C2’’ and C6’’), 
66.9 (C3’ and C4’), 64.3 (C2’ and C5’), 57.0 (C3’’ and C5’’), 
19.2 (CH3). HRMS exact mass calcd. for C24H26N3O2
56
Fe [MH]
+
, 
requires m/z 444.1374, found m/z 444.1379. 
 
2-ferrocenyl-4-(phenethylamino)phthalazin-1(2H)-one (5e) 
Orange solid; Yield: 67.4 mg (15%); mp: 170.9-173.3 °C (from 
EtOH); IR (ATR, cm
-1
): 3345, 1632, 1579, 1537, 1497, 1478, 
1452, 1428, 1381, 1328, 1313, 1229, 1185, 1167, 1151, 1119, 
1108, 1048, 1026, 1003, 925, 801, 771, 747, 719, 701, 687, 646, 
613, 586, 474, 455, 406; 
1
H-NMR (DMSO-d6): 8.33 (1H, d, J = 
7.5 Hz, H5), 8.14 (1H, d, J = 8.1 Hz, H8), 7.92 (1H, t, J = 7.3 Hz, 
H6), 7.85 (1H, t, J = 7.5 Hz, H7), 7.39-7.33 (4H, m, H2’’ and 
H3’’ and H5’’ and H6’’), 7.24 (1H, tt, J = 7.3 Hz, 2.0 Hz, H4’’), 
7.11 (1H, t, J = 5.0 Hz, NH), 5.20 (2H, br s, H2’ and H5’), 4.19 
(2H, br s, H3’ and H4’) 4.13 (5H, s, η
5
-C5H5), 3.64 (2H, td, J = 
7.4 Hz, 5.0 Hz, CH2NH), 3.11 (2H, t, J = 7.4 Hz, CH2Ph); 
13
C-
NMR (DMSO-d6): 156.5 (C1), 144.6 (C4), 140.6 (C4a), 133.3 
(C6), 132.1 (C7), 129.1 (C2’’ and C6’’), 128.9 (C3’’ and C5’’), 
128.6 (C8a), 127.3 (C5), 126.5 (C4’), 124.4 (C1’’), 123.4 (C8), 
100.7 (C1’), 69.6 (η
5
-C5H5), 65.5 (C3’ and C4’), 63.5 (C2’ and 
C5’), 43.8 (CH2NH), 34.7 (CH2Ph). HRMS exact mass calcd. for 
C26H24N3O
56
Fe [MH]
+
, requires m/z 450.1269, found m/z 
450.1277. 
 
4-((2-acetoxypropyl)amino)-2-ferrocenyl-phthalazin-1(2H)-one 
(5f) 
Yellow solid; Yield: 71.6 mg (16%); mp.: 133.9-135.2 °C (from 
EtOH); IR (ATR, cm
-1
): 3420, 1715, 1651, 1590, 1544, 1483, 
1463, 1443, 1412, 1398, 1366, 1340, 1329, 1309, 1287, 1260, 
1195, 1173, 1154, 1134, 1118, 1105, 1089, 1035, 1026, 1016, 
982, 929, 858, 815, 795, 768, 720, 680, 643, 629, 605, 505, 496, 
481, 457, 441, 422, 401; 
1
H-NMR (DMSO-d6): 8.32 (1H, d, J = 
7.9 Hz, H8), 8.14 (1H, d, J = 5.1 Hz, H5), 7.92 (1H, t, J = 7.6 
Hz, H6), 7.85 (1H, t, J = 7.6 Hz, H7), 7.03 (1H, t, J = 4.9 Hz, 
NH), 5.19 (2H, br s, H2’ and H5’), 4.20 (2H, t, J = 6.3 Hz, 
CH2O), 4.17 (2H, br s, H3’ and H4’), 4.13 (5H, s, η
5
-C5H5), 3.49 
(2H, q, J = 6.0 Hz, CH2NH), 2.10 (2H, p, J = 6.3 Hz, 
CH2CH2CH2), 2.04 (3H, s, CH3); 
13
C-NMR (DMSO-d6): 171.0 
(CH3COO), 156.4 (C1), 144.6 (C4), 133.2 (C7), 132.0 (C6), 
128.6 (C8a), 127.4 (C8), 124.4 (C4a), 123.4 (C5), 100.7 (C1’), 
69.4 (η
5
-C5H5), 65.4 (C3’ and C4’), 63.5 (C2’ and C5’), 62.8 
(CH2O), 38.7 (CH2NH), 27.9 (CH2CH2CH2), 21.3 (CH3). HRMS 
exact mass calcd. for C23H24N3O3
56
Fe [MH]
+
, requires m/z 
446.1167, found m/z 446.1174.  
 
2-ferrocenyl-4-(2-hydroxyethoxy)phthalazin-1(2H)-one (5g) 
Orange solid; Yield: 103.1 mg (26%); mp.: 152.6-153.5 °C (from 
EtOH); IR (ATR, cm
-1
): 3428, 3087, 2944, 1636, 1619, 1587, 
1495, 1454, 1410, 1384, 1348, 1316, 1240, 1187, 1102, 1079, 
1027, 1017, 1000, 967, 930, 899, 858, 825, 809, 794, 778, 728, 
690, 644, 574, 485, 457, 442; 
1
H-NMR (DMSO-d6): 8.31 (1H, d, 
J = 7.7 Hz, H8), 8.09 (1H, d, J = 7.6 Hz, H5), 7.97 (1H, td, J = 
7.5 Hz, 1.5 Hz, H6), 7.93 (1H, td, J = 7.5 Hz, 1.5 Hz, H7), 5.14 
(2H, t, J = 2.0 Hz, H2’ and H5’), 5.03 (1H, t, J = 5.7 Hz, OH), 
4.46 (2H, t, J = 4.9 Hz, COCH2), 4.21 (2H, t, J = 2.0 Hz, H3’ and 
H4’), 4.18 (5H, s, η
5
-C5H5), 3.90 (2H, q, J = 5.2 Hz, CH2OH); 
13
C-NMR (DMSO-d6): 157. (C1), 149.5 (C4), 134.0 (C6), 133.0 
(C7), 127.2 (C8), 129.3 (C8a), 124.1 (C5), 123.9 (C4a), 69.8 (η
5
-
C5H5), 69.2 (COCH2), 65.0 (C3’ and C4’), 63.8 (C2’ and C5’), 
60.0 (CH2OH). HRMS exact mass calcd. for C20H19N2O3
56
Fe 
[MH]
+
, requires m/z 391.0745, found m/z 391.0752. 
 
2-ferrocenyl-4-((2-hydroxyethyl)amino)-8-nitrophthalazin-1(2H)-
one (5h) 
Dark red solid; Yield: 70.4 mg (16%); mp.: 199.9-201.4 °C (from 
EtOH); IR (ATR, cm
-1
): 3574, 3336, 1643, 1582, 1538, 1521, 
1455, 1399, 1376, 1343, 1331, 1299, 1238, 1168, 1122, 1106, 
1076, 1045, 1032, 1002, 951, 876, 864, 849, 824, 812, 803, 779, 
761, 725, 705, 676, 642, 540, 496, 486, 456, 434, 387, 375; 
1
H-
NMR (DMSO-d6): 8.39 (1H, d, J = 7.4 Hz, H5), 8.12 (1H, d, H7, 
overlapped by H6), 8.09 (1H, t, H6, overlapped by H7), 7.14 
(1H, br t, NH), 5.06 (2H, s, H2’ and H5’), 4.78 (1H, t, J = 5.3 Hz, 
OH), 4.18 (2H, s, H3’ and H4’), 4.15 (5H, s, η
5
-C5H5), 3.76 (2H, 
q, J = 5.6 Hz, CH2OH), 3.49 (2H, q, J = 5.5 Hz, CH2NH); 
13
C-
NMR (DMSO-d6): 152.6 (C1), 149.4 (C8), 143.9 (C4), 134.3 
(C6), 131.4 (C4a), 126.3 (C7), 126.0 (C5), 118.9 (C8a), 99.9 
(C1’), 69.7 (η
5
-C5H5), 65.7 (C3’ and C4’ and CH2OH), 63.8 (C2’ 
and C5’), 44.8 (CH2NH); HRMS exact mass calcd. for 
C20H19N4O4
56
Fe [MH]
+
, requires m/z 435.0756, found m/z 
435.0765. 
 
4-((2-acetoxyethyl)amino)-2-ferrocenyl-8-nitrophthalazin-1(2H)-
one (5i) 
Dark red solid; Yield: 172.6 mg (36%); mp.: ~220 (degr.) °C 
(from EtOH); IR (ATR, cm
-1
): 3418, 1723, 1641, 1588, 1534, 
1463, 1454, 1444, 1410, 1380, 1363, 1333, 1308, 1230, 1174, 
1156, 1139, 1105, 1027, 1000, 958, 931, 914, 886, 851, 812, 801, 
775, 761, 725, 699, 676, 643, 610, 570, 494, 459, 441, 405; 
1
H-
NMR (DMSO-d6): 8.36 (1H, d, J = 7.5 Hz, H5), 8.14 (1H, br d, J 
= 8.4 Hz, H7), 8.10 (1H, t, J = 8.0 Hz, H6), 7.34 (1H, t, J = 5.4 
Hz, NH), 5.08 (2H, s, H2’ and H5’), 4.18 (2H, s, H3’ and H4’), 
4.16 (5H, s, η
5
-C5H5), 4.40 (2H, t, J = 5.7 Hz, CH2OH), 3.67 (2H, 
q, J = 5.5 Hz, CH2NH), 2.04 (3H, s, CH3); 
13
C-NMR (DMSO-d6): 
171.0 (CH3COO), 154.7 (C1), 149.4 (C8), 143.8 (C4), 134.4 
(C6), 126.2 (C5), 126.1 (C7), 125.8 (C4a), 119.0 (C8a), 99.9 
(C1’), 69.6 (η
5
-C5H5), 65.8 (C3’ and C4’), 63.8 (C2’ and C5’), 
62.0 (CH2O), 41.0 (CH2NH), 21.4 (CH3). HRMS exact mass 
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calcd. for C22H21N4O5
56
Fe [MH]
+
, requires m/z 477.0861, found 
m/z 477.0856.  
 
2-ferrocenyl-4-((2-hydroxyethyl)amino)-8-
(phenylthio)phthalazin-1(2H)-one (5j) 
Orange solid; Yield: 203.1 mg (41%); mp.: 165.3-167.9 °C (from 
EtOH); IR (ATR, cm
-1
): 3297, 1625, 1595, 1570, 1534, 1458, 
1438, 1307, 1237, 1194, 1166, 1135, 1104, 1070, 1053, 1024, 
998, 944, 910, 837, 818, 805, 778, 751, 698, 690, 647, 567, 534, 
493, 459, 433, 411; 
1
H-NMR (DMSO-d6): 7.80 (1H, d, J = 5.6 
Hz, H5), 7.65-7.51 (6H, m, H6 and H2’’– H6’’), 6.84 (1H, d, J = 
6.4 Hz, H7), 6.79 (1H, br t, NH), 5.13 (2H, s, H2’ and H5’), 4.74 
(1H, br t, OH), 4.17 (7H, s, H3’ and H4’ and η
5
-C5H5), 3.75 (2H, 
br s, CH2OH), 3.48 (2H, br s, CH2NH); 
13
C-NMR (DMSO-d6): 
156.8 (C1), 144.6 (C4 and C8), 136.4 (C3’’ and C5’’), 132.7 
(C6), 132.6 (C1’’), 130.9 (C2’’ and C6’’), 130.3 (C4’’), 128.1 
(C7), 126.0 (C4a), 123.5 (C8a), 119.0 (C5), 100.5 (C1’), 69.5 
(η
5
-C5H5), 65.4 (C3’ and C4’), 63.7 (C2’ and C5’), 59.4 
(CH2OH), 44.8 (CH2NH); HRMS exact mass calcd. for 
C26H24N3O2S
56
Fe [MH]
+
, requires m/z 498.0939, found m/z 
498.0946. 
 
2-ferrocenyl-4-((2-hydroxyethyl)amino)-8-(pyrrolidin-1-
yl)phthalazin-1(2H)-one (5k) 
Yellowish orange solid; Yield: 104.4 mg (23%); mp.: 198.1-
199.5 °C (from EtOH); IR (ATR, cm
-1
): 3320, 2871, 2819, 1618, 
1528, 1470, 1459, 1436, 1392, 1376, 1356, 1338, 1319, 1298, 
1290, 1247, 1224, 1194, 1161, 1147, 1119, 1105, 1027, 997, 867, 
848, 814, 797, 787, 757, 711, 702, 665, 634, 566, 532, 494, 841, 
449, 420; 
1
H-NMR (DMSO-d6): 7.57 (1H, t, J = 8.0 Hz, H6), 
7.26 (1H, d, J = 7.7 Hz, H5), 7.07 (1H, d, J = 8.5 Hz, H7), 6.44 
(1H, br t, J = 5.5 Hz, NH), 5.09 (2H, s, H2’ and H5’), 4.73 (1H, 
br t, J = 5.6 Hz, OH), 4.11 (7H, s, H3’ and H4’ and η
5
-C5H5), 
3.75 (2H, br q, J = 6.1 Hz, CH2OH), 3.45 (2H, br q, J = 5.9 Hz, 
CH2NH), 3.34 (4H, s, H2’’ and H5’’), 1.90 (4H, br s, H3’’ and 
H4’’); 
13
C-NMR (DMSO-d6): 156.1 (C1), 149.5 (C8), 144.9 
(C4), 132.6 (C6), 127.2 (C4a), 115.6 (C7), 113.9 (C8a), 109.9 
(C5), 101.5 (C1’), 69.2 (η
5
-C5H5), 65.0 (C3’ and C4’), 63.1 (C2’ 
and C5’), 59.7 (CH2OH), 52.0 (C2’’ and C5’’), 44.8 (CH2NH), 
25.9 (C3’’ and C4’’); HRMS exactmassC24H27N4O2
56
Fe [MH]
+
, 
requires m/z 459.1483, found m/z 459.1489.  
 
2-ferrocenyl-4-((2-hydroxyethyl)amino)-8-((2-(piperidin-1-
yl)ethyl)amino)phthalazin-1(2H)-one (5l) 
Yellow solid; Yield: 100.1 mg (19%); mp.: 180.5-182.0 °C (from 
EtOH); IR (ATR, cm
-1
): 3361, 2924, 2853, 1640, 1595, 1570, 
1537, 1467, 1404, 1363, 1324, 1297, 1269, 1255, 1220, 1209, 
1189, 1160, 1129, 1117, 1105, 1092, 1072, 1036, 1020, 1000, 
860, 837, 812, 802; 
1
H-NMR (DMSO-d6): 9.50 (1H, t, J = 4.6 
Hz, 8-NH), 7.59 (1H, t, J = 7.9 Hz, H6), 7.09 (1H, d, J = 7.7 Hz, 
H5), 6.86 (1H, d, J = 8.7 Hz, H7), 6.55 (1H, t, J = 5.4 Hz, 4-NH), 
5.09 (2H, t, J = 2.0 Hz, H2’ and H5’), 4.75 (1H, t, J = 5.0 Hz, 
OH), 4.14 (7H, m, H3’ and H4’ and η
5
-C5H5), 3.74 (2H, q, J = 
5.5 Hz, CH2OH), 3.46 (2H, q, J = 5.7 Hz, CH24-NH), 3.30 (2H, 
q, J = 5.5 Hz, CH28-NH), 2.58 (2H, t, J = 6.4 Hz, CH2Pip), 2.43 
(4H, br s, H2’’ and H6’’), 1.55 (4H, p, J = 5.6 Hz, H3’’ and 
H5’’), 1.42 (2H, q, J = 5.6 Hz, H4’’); 
13
C-NMR (DMSO-d6): 
159.5 (C1), 150.9 (C8), 145.1 (C4), 134.6 (C6), 125.9 (C4a), 
111.8 (C7), 110.4 (C8a), 107.6 (C5), 100.7 (C1’), 69.4 (η
5
-C5H5), 
65.2 (C3’ and C4’), 63.7 (C2’ and C5’), 59.6 (CH2OH), 57.1 
(CH2Pip), 54.4 (C2’’ and C6’’), 44.7 (CH24-NH), 40.3 (CH28-
NH, overlapped by solvent signal), 26.1 (C3’’ and C5’’), 24.6 
(C4’’); HRMS exact mass calcd. for C27H34N5O2
56
Fe [MH]
+
, 
requires m/z 516.2062, found m/z 516.2056.  
 
2-ferrocenyl-4,8-bis((2-hydroxyethyl)amino)phthalazin-
1(2H)-one (5m) 
Yellow solid; Yield: 31.2 mg (7%); mp.: 222.3-224.1 (degr.) °C 
(from EtOH); IR (ATR, cm
-1
): 3374, 2841, 1634, 1588, 1570, 
1528, 1470, 1450, 1404, 1377, 1350, 1323, 1299, 1248, 1234, 
1214, 1187, 1165, 1134, 1105, 1092, 1063, 1024, 1000, 980, 893, 
874, 837, 812, 802, 762, 701, 686, 672, 633, 574, 539, 498, 491, 
462, 448, 418; 
1
H-NMR (DMSO-d6): 9.48 (1H, t, J = 4.4 Hz, 8-
NH), 7.57 (1H, t, J = 7.8 Hz, H6), 7.09 (1H, d, J = 7.8 Hz, H5), 
6.86 (1H, d, J = 8.3 Hz, H7), 6.56 (1H, t, J = 4.4 Hz, 4-NH), 5.08 
(2H, br s, H2’ and H5’), 4.88 (1H, t, J = 4.9 Hz, 8-OH), 4.74 (1H, 
t, J = 5.3 Hz, 4-OH), 4.13 (5H, s, η
5
-C5H5), 3.74 (2H, q, J = 5.8 
Hz, 4-CH2OH), 3.66 (2H, q, J = 5.2 Hz, 8-CH2OH), 3.45 (2H, q, 
J = 5.5 Hz, 4-CH2NH), 3.27 (2H, q, J = 5.0 Hz, 8-CH2NH); 
13
C-
NMR (DMSO-d6): 159.6 (C1), 151.1 (C8), 145.1 (C4), 134.7 
(C6), 125.9 (C4a), 111.7 (C7), 110.3 (C8a), 107.6 (C5), 100.6 
(C1’), 69.4 (η
5
-C5H5), 65.2 (C3’ and C4’), 63.7 (C2’ and C5’), 
59.7 (8-CH2OH), 59.6 (4-CH2OH), 45.3 (4-CH2NH), 44.7 (4-
CH2NH); HRMS exact mass calcd. for C22H25N4O3
56
Fe [MH]
+
, 
requires m/z 449.1276, found m/z 449.1270. 
 
(E)-8-(2-benzylidene-1-methylhydrazinyl)-2-ferrocenyl-4-((2-
hydroxyethyl)amino) phthalazin-1(2H)-one (5o) 
Reddish orange solid; Yield: 96.6 mg (19%); mp.: 185.9-187.5 
°C (from EtOH); IR (ATR, cm
-1
): 3311, 1629, 1593, 1569, 1543, 
1468, 1448, 1431, 1382, 1360, 1318, 1228, 1192, 1178, 1155, 
1125, 1105, 1087, 1059, 1028, 992, 936, 920, 888, 811, 804, 790, 
768, 752, 703, 692, 669, 642, 620, 586, 542, 498, 475, 451; 
1
H-
NMR (DMSO-d6): 7.83-7.82 (2H, m, H5 and H7), 7.78 (1H, q, J 
= 4.6 Hz, H6), 7.74 (1H, s, CHPh), 7.71 (2H, d, J = 7.4 Hz, H2’’ 
and H6’’), 7.40 (2H, t, J = 7.5 Hz, H3’’ and H5’’), 7.29 (1H, t, J 
= 7.3 Hz, H4’’), 6.75 (1H, t, J = 5.4 Hz, NH), 5.12 (2H, s, J = 2.0 
Hz, H2’ and H5’), 4.80 (1H, br s, OH), 4.15 (2H, t, H3’ and H4’, 
overlapped byη
5
-C5H5 signal), 4.14 (5H, s, η
5
-C5H5, overlapped 
by H3’ and H4’), 3.78 (2H, t, J = 7.8 Hz, CH2OH), 3.47 (2H, q, J 
= 6.0 Hz, CH2NH), 3.31 (3H, s, CH3, overlapped by solvent 
signal); 
13
C-NMR (DMSO-d6): 155.0 (C1), 149.8 (C8), 144.5 
(C4), 137.0 (C1’’), 134.4 (PhCH), 133.0 (C6), 129.1 (C3’’ and 
C5’’), 128.1 (C4’’), 126.8 (C5), 126.7 (C4a), 126.3 (C2’’ and 
C6’’), 118.9 (C8a), 118.2 (C7), 101.2 (C1’), 69.4 (η
5
-C5H5), 65.3 
(C3’ and C4’), 63.7 (C2’ and C5’), 59.6 (CH2OH), 44.8 
(CH2NH), 41.9 (CH3); HRMS exact mass calcd for 
C28H28N5O2
56
Fe [MH]
+
, requires m/z 522.1592, found m/z 
522.1599.  
 
(E)-8-(2-ferrocenylidene-1-methylhydrazinyl)-2-ferrocenyl-4-((2-
hydroxyethyl)amino) phthalazin-1(2H)-one (5p) 
Orange solid; Yield: 204.5 mg (33%); mp.: 189.7-192.8 °C (from 
EtOH); IR (ATR, cm
-1
): 3358, 2918, 1626, 1567, 1550, 1463, 
1434, 1413, 1383, 1363, 1321, 1250, 1224, 1209, 1175, 1153, 
1121, 1106, 1090, 1068, 1022, 994, 935, 880, 810, 793, 772, 700, 
669, 581, 497, 483, 457, 420; 
1
H-NMR (DMSO-d6): 7.81-7.68 
(3H, m, H5 and H6 and H7), 7.52 (1H, s, CHFc), 6.68 (1H, br t, 
NH), 5.11 (2H, s, H2’ and H5’), 4.75 (1H, br t, OH), 4.62 (2H, s, 
H2’’ and H5’’), 4.32 (2H, s, H3’’ and H4’’), 4.19 (5H, s, 8-η
5
-
C5H5), 4.13 (7H, s, H3’ and H4’ and 2-η
5
-C5H5), 3.77 (2H, br q, J 
= 5.1 Hz, CH2OH), 3.47 (2H, br q, J = 4.6 Hz, CH2NH), 3.21 
(3H, s, CH3); 
13
C-NMR (DMSO-d6): 155.2 (C1), 150.2 (C8), 
144.6 (C4), 134.7 (FcCH) 133.0 (C6), 126.7 (C4a), 125.9 (C5), 
118.2 (C8a), 117.2 (C7), 101.2 (C1’), 83.1 (C1’’), 69.5 (1-η
5
-
C5H5), 69.4 (8-η
5
-C5H5) 69.3 (C3’’ and C4’’), 67.0 (C2’’ and 
C5’’), 65.2 (C3’ and C4’), 63.7 (C2’ and C5’), 59.6 (CH2OH), 
44.8 (CH2NH), 42.1 (CH3); HRMS exact mass calcd.for 
C32H32N5O2
56
Fe2 [MH]
+
, requires m/z 630.1255, found m/z 
630.1247.  
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7-ferrocenyl-5-((2-hydroxyethyl)amino)pyrido[2,3-d]pyridazin-
8(7H)-one (7a) 
Orange solid; Yield: 13.3 mg (3%); 
1
H-NMR (DMSO-d6): 9.06 
(1H, br d, J = 4.3 Hz, H2), 8.84 (1H, br d, J = 8.3 Hz, H4), 7.92 
(1H, dd, J = 8.3 Hz, 4.3 Hz, H3), 7.33 (1H, br t, NH), 5.17 (2H, t, 
J = 1.9 Hz, H2’ and H5’), 4.98 (1H, br t, J = 6.0 Hz, OH), 4.19 
(2H, t, J = 1.9 Hz, H3’ and H4’), 4.16 (5H, s, η
5
-C5H5), 3.77 (2H, 
q, J = 5.6 Hz, CH2OH, overlapped), 3.48 (2H, q, J = 5.6 Hz, 
CH2NH); 
13
C-NMR (DMSO-d6): 154.6 (C8), 154.1 (C2), 144.4 
(C5), 143.6 (C4a), 132.8 (C4), 127.5 (C3), 121.7 (C8a), 101.0 
(C1’), 69.7 (η
5
-C5H5), 65.6 (C3’ and C4’), 64.0 (C2’ and C5’), 
60.0 (CH2OH), 45.0 (CH2NH); HRMS exact mass calcd. for 
C19H19N4O2
56
Fe [MH]
+
, requires m/z 391.0857, found m/z 
391.0864.  
 
2-ferrocenyl-4-((2-hydroxyethyl)amino)pyrido[3,4-d]pyridazin-
1(2H)-one (7b) 
Red solid; Yield: 83.0 mg (21%); mp.: 209.2-210.3 °C (from 
EtOH); IR (ATR, cm
-1
): 3311, 1633, 1608, 1569, 1528, 1461, 
1410, 1394, 1346, 1321, 1300, 1241, 1219, 1175, 1146, 1117, 
1107, 1081, 1065, 1046, 1025, 999, 929, 901, 847, 804, 793, 741, 
693, 685, 669, 624, 563, 487, 464, 379; 
1
H-NMR (DMSO-d6): 
9.53 (1H, br s, H5), 9.00 (1H, br s, H7), 8.13 (1H, d, J = 4.6 Hz, 
H8), 7.24 (1H, t, J = 5.4 Hz, NH), 5.16 (2H, s, H2’ and H5’), 
4.80 (1H, t, J = 5.4 Hz, OH), 4.20 (2H, s, H3’ and H4’), 4.16 
(5H, s, η
5
-C5H5), 3.79 (2H, q, J = 5.4 Hz, CH2OH), 3.51 (2H, q, J 
= 5.4 Hz, CH2NH);
13
C-NMR (DMSO-d6): 155.1 (C1), 151.7 
(C7), 147.1 (C5), 143.9 (C4), 134.0 (C8a), 119.5 (C8), 119.0 
(C4a), 100.8 (C1’), 69.6 (η
5
-C5H5), 65.7 (C3’ and C4’), 63.7 (C2’ 
and C5’), 59.3 (CH2OH), 44.6 (CH2NH); HRMS exact mass 
calcd.for C19H19N4O2
56
Fe [MH]
+
, requires m/z 391.0857, found 
m/z 391.0850.  
 
6-ferrocenyl-2-phenylpyridazin-3(2H)-one (2a) 
Orange solid, Yield: 184.6 mg (52%); mp.: 156.0-157.9 °C (from 
EtOH); IR (ATR, cm
-1
): 1664, 1601, 1489, 1454, 1388, 1303, 
1280, 1262, 1207, 1170, 1124, 1106, 1092, 1022, 1007, 912, 897, 
839, 817, 764, 727, 689, 655, 642, 623, 610, 581, 564, 513, 491, 
479, 443, 429, 391, 377; 
1
H-NMR (DMSO-d6): 7.81 (1H, d, J = 
9.6 Hz, H5), 7.60 (2H, d, J = 7.8 Hz, H2’ and H6’), 7.51 (2H, t, J 
= 7.8 Hz, H3’ and H5’), 7.42 (1H, t, J = 7.4 Hz, H4’), 7.05 (1H, 
d, J = 9.6 Hz, H4), 4.83 (2H, t, J = 1.9 Hz, H2’’ and H5’’), 4.46 
(2H, t, J = 1.9 Hz, H3’’ and H4’’), 4.18 (5H, s, η
5
-C5H5); 
13
C-
NMR (DMSO-d6): 159.1 (C1), 146.8 (C4), 142.1 (C1’), 132.4 
(C5), 130.6 (C4), 129.0 (C3’ and C5’), 128.2 (C4’), 126.0 (C1’ 
and C6’), 80.9 (C1’’), 70.7 (C3’’ and C4’’), 69.9 (η
5
-C5H5), 67.2 
(C2’’ and C5’’); HRMS exact mass calcd. for C20H17N2O
56
Fe 
[MH]
+
, requires m/z 357.0690, found m/z 357.0682.  
 
6-ferrocenyl-2-(pyridin-2-yl)pyridazin-3(2H)-one (2b) 
Red solid, Yield: 228.8 mg (64%); mp.: 156.0-157.9 °C (from 
EtOH); IR (ATR, cm
-1
): 1662, 1597, 1584, 1570, 1508, 1492, 
1462, 1431, 1407, 1387, 1310, 1297, 1285, 1251, 1214, 1178, 
1149, 1131, 1106, 1097, 1056, 1038, 1026, 1013, 999, 992, 967, 
897, 856, 848, 838, 828, 819, 793, 751, 739, 650, 629, 610, 590, 
582, 571, 523, 498, 484, 449, 434, 414, 389, 379; 
1
H-NMR 
(DMSO-d6): 8.62 (1H, ddd, J = 4.8 Hz, 1.9 Hz, 0.9 Hz, H6’), 
8.02 (1H, td, J = 7.7 Hz, 1.9 Hz, H4’) 7.86 (1H, d, J = 9.7 Hz, 
H5), 7.61 (1H, dt, J = 8.0 Hz, 1.0 Hz, H3’), 7.53 (1H, ddd, J = 
4.8 Hz, 1.9 Hz, 0.9 Hz, H5’), 7.08 (1H, d, J = 9.7 Hz, H4), 4.79 
(2H, t, J = 1.9 Hz, H2’’ and H5’’), 4.46 (2H, t, J = 1.9 Hz, H3’’ 
and H4’’), 4.19 (5H, s, η
5
-C5H5); 
13
C-NMR (DMSO-d6): 159.2 
(C1), 153.9 (C2’), 149.5 (C6’), 146.5 (C4), 139.1 (C4’), 133.2 
(C5), 130.6 (C4), 124.7 (C5’), 122.3 (C3’), 80.0 (C1’’), 70.7 
(C3’’ and C4’’), 69.9 (η
5
-C5H5), 67.3 (C2’’ and C5’’); HRMS 
exact mass calcd. for C19H16N3O
56
Fe [MH]
+
, requires m/z 
358.0643, found m/z 358.0651. 
 
2-phenylphthalazin-1(2H)-one (5aa) 
White solid, Yield: 46.2 mg (21%); mp.: 107.6-109.0 °C (from 
EtOH); IR (ATR, cm
-1
): 3360, 2917, 2848, 1654, 1584, 1488, 
1452, 1363, 1326, 1309, 1291, 1241, 1200, 1151, 1135, 1121, 
1075, 1059, 1017, 971, 903, 871, 863, 844, 820, 793, 764, 734, 
706, 686, 617, 598, 583, 537, 483, 466, 431, 421, 405, 391, 380; 
1
H-NMR (DMSO-d6): 8.59 (1H, s, H4), 8.33 (1H, d, J = 8.0 Hz, 
H8), 8.03 (1H, dd, J = 8.4 Hz, 1.4 Hz, H5, overlapped by H6), 
8.00 (H6, td, J = 8.3 Hz, 1.2 Hz, 1H, overlapped by H5), 7.92 
(1H, ddd, J = 7.9 Hz, 6.8 Hz, 1.8 Hz, H7), 7.62 (2H, dt, J = 7.4 
Hz, 1.3 Hz, H2’ and H6’), 7.53 (2H, tt, J = 8.2 Hz, 1.3 Hz, H3’ 
and H5’), 7.43 (1H, tt, J = 7.4 Hz, 1.7 Hz, H4’); 
13
C-NMR 
(DMSO-d6): 158.8 (C1), 142.3 (C1’), 139.2 (C4), 134.4 (C6), 
132.8 (C7), 129.7 (C4a), 129.0 (C3’ and C5’), 128.2 (C8a), 128.0 
(C4’), 127.5 (C5), 126.7 (C8), 126.5 (C2’ and C6’); HRMS exact 
mass calcd for C14H11N2O [MH]
+
, requires m/z 223.0871, found 
m/z 223.0867. 
 
2-(pyridin-2-yl)phthalazin-1(2H)-one (5ab) 
Beige solid, Yield: 245.5 mg (37%); mp.: 120.2-123.7 °C (from 
EtOH); IR (ATR, cm
-1
): 3040, 1666, 1587, 1482, 1465, 1450, 
1442, 1365, 1333, 1295, 1241, 1163, 1151, 1074, 1043, 992, 915, 
876, 802, 787, 761, 739, 711, 682, 623, 598, 589, 541, 486, 469, 
412, 404; 
1
H-NMR (CDCl3): 8.71 (1H, br s, H6’), 8.52 (1H, d, J 
= 7.9 Hz, H8), 8.37 (1H, d, J = 6.7 Hz, H5), 7.90 (1H, td, J = 7.1 
Hz, 1.6 Hz, H5’, overlapped by H6), 7.88 (1H, td, J = 7.1 Hz, 1.1 
Hz, H6, overlapped by H5’), 7.83 (1H, td, J = 7.4 Hz, 1.1 Hz, 
H7), 7.80 (1H, d, J = 7.1 Hz, H3’, overlapped by H5), 7.78 (1H, 
d, J = 6.7 Hz, H5, overlapped by H3’), 7.37 (1H, dd, J = 7.4 Hz, 
1.8 Hz, H4’); 
13
C-NMR (CDCl3): 159.3 (C1), 153.3 (C2’), 149.3 
(C6’), 139.0 (C4), 137.8 (C5’), 133.8 (C6), 132.1 (C7), 129.6 
(C4a), 128.6 (C8a), 127.3 (C8), 126.2 (C5), 123.2 (C4’), 121.3 
(C3’); HRMS exact mass calcd for C13H10N3O [MH]
+
, requires 
m/z 224.0824, found m/z 224.0818.  
 
4-((2-hydroxyethyl)amino)-2-phenyl-8-((2-(piperidin-1-
yl)ethyl)amino)phthalazin-1(2H)-one (5la) 
Bright yellow solid; Yield: 95.1 mg (23%); mp.: 77.4-80.7 °C 
(from EtOH); IR (ATR, cm
-1
):3277, 2929, 2851, 1634, 1601, 
1565, 1524, 1487, 1455. 1408, 1292, 1236, 1203, 1155, 1114. 
1087, 1049, 962, 909, 857, 805, 755, 693, 665, 617, 518, 480, 
460, 423, 410, 389, 375; 
1
H-NMR (DMSO-d6): 9.32 (1H, t, J = 
5.0 Hz, 8-NH), 7.63 (2H, d, J = 7.9 Hz, H2’ and H6’, overlapped 
by H6), 7.62 (1H, t, J = 8.1 Hz, H6, overlapped by H2’ and H6’), 
7.46 (2H, t, J = 7.9 Hz, H3’ and H5’), 7.32 (1H, tt, J = 7.4 Hz, 
1.3 Hz, H4’), 7.13 (1H, d, J = 7.8 Hz, H5), 6.88 (1H, d, J = 8.4 
Hz, H7), 6.48 (1H, t, J = 5.4 Hz, 4-NH), 4.66 (1H, t, J = 5.6 Hz, 
OH), 3.63 (2H, q, J = 5.5 Hz, CH2OH), 3.33 (2H, q, J = 5.8 Hz, 
CH24-NH), 3.26 (2H, q, J = 5.0 Hz, CH28-NH), 2.54 (2H, t, J = 
6.4 Hz, CH2Pip), 2.39 (4H, br s, H2’’ and H6’’), 1.49 (4H, p ,J = 
5.5 Hz, H3’’ and H5’’), 1.38 (2H, q ,J = 5.9 Hz, H4’’); 
13
C-NMR 
(DMSO-d6): 159.9 (C1), 151.2 (C8), 145.6 (C4), 143.1 (C1’), 
135.0 (C6), 128.7 (C3’ and C5’), 126.7 (C4’), 126.6 (C4a), 126.2 
(C2’ and C6’), 111.8 (C7), 110.4 (C8a), 107.7 (C5), 59.7 
(CH2OH), 57.3 (CH2Pip), 54.5 (C2’’ and C6’’), 44.5 (CH24-NH), 
40.3 (CH28-NH, overlapped by solvent signal), 28.0 (C3’’ and 
C5’’), 24.5 (C4’’); HRMS exact mass calcd for C23H30N5O2 
[MH]
+
, requires m/z 408.2399, found m/z 408.2391.  
 
Cytotoxicity Assay 
The adherent HepG2 human hepatoma cells
35
 and HT-29 human 
colorectal adenocarcinoma cells
36
 were cultured in RPMI-1640 
medium supplemented with 10% FCS (fetal calf serum, Sigma 
 13 
Ltd.), 2 mM l-glutamine, and 160 μg/mL gentamicin. Cell 
cultures were maintained at 37 °C in a humidified atmosphere 
with 5% CO2. 
The cells were grown to confluency and were distributed into 96-
well plate with initial cell number of 5.0x10
3
 per well. After 24 h 
incubation at 37 
o
C, the cells were treated with the compounds in 
200 μL final volume containing 1.0 v/v% DMSO. The cells were 
incubated with the compounds at 10
-4 
-10
2
 μM concentration 
range for overnight. Control cells were treated with serum free 
medium (RPMI-1640) only or with DMSO (c=1.0 v/v %) at 37 
o
C for overnight. After incubation the cells were washed twice 
with serum free (RPMI-1640) medium. To determine the in vitro 
cytostatic effect, the cells were cultured for a further 72 h in 10% 
serum containing medium. MTT-solution (45 μL, 2 mg/mL, final 
concentration: 0.37 μg/mL) was added to each well. The 
respiratory chain
37
 and other electron transport systems
38
 reduce 
MTT and thereby form non-water-soluble violet formazane 
crystals within the cell.
39
 The amount of these crystals can be 
determined spectrophotometrically and serves as an estimate for 
the number of mitochondria and hence the number of living cells 
in the well.
40
 After 4 h of incubation the cells were centrifuged 
for 5 min (900 g) and the supernatant was removed. The obtained 
formazane crystals were dissolved in DMSO (100 μL) and 
optical density (OD) of the samples was measured at =540 and 
620 nm, respectively, using ELISA Reader (iEMS Reader, 
Labsystems, Finland). OD620 values was substracted from OD540 
values. The percent of cytostasis was calculated by using the 
following equation:  
Cytostatic effect (%) = [1 – (ODtreated/ODcontrol)] x100  
Values ODtreated and ODcontrol correspond to the optical densities 
of the treated and the control cells, respectively. In each case two 
independent experiments were carried out with 4 parallel 
measurements. The 50% inhibitory concentration (IC50) values 
were determined from the dose-response curves. The curves were 
defined using Microcal TM Origin1 (version 7.5) software: 
cytostasis was plotted as a function of concentration, fitted to a 
sigmoidal curve, and based on this curve, the half maximal 
inhibitory concentration (IC50) value was determined. IC50 
represents the concentration of a compound that is required for 
50% inhibition in vitro and expressed in micromolar units. 
 
Cyclic voltammetry assay 
The samples were investigated by CV in a conventional three-
electrode electrochemical glass cell with a Biologic SP150 
potentiostat and the EC-LAB software package. The three-
electrode system comprised a glassy carbon working electrode 
(d = 0.3 cm, geometric surface area A = 0.0707 cm
2
), a Pt wire 
counter electrode and an Ag/AgCl reference electrode, but all 
potentials are given on the reversible hydrogen electrode (RHE) 
scale. Before each measurement, the glassy carbon working 
electrode was polished with 0.05 µm alumina to obtain a mirror 
finish and then cleaned ultrasonically and dried to remove any 
traces of organic impurities. Each sample was dissolved in the 
electrolyte solution [0.1 mm tetrabutylammonium 
hexafluorophosphate in acetonitrile] at a concentration of 1 mm; 
the solution was then bubbled with Ar for 15 min. The CV 
measurements were performed in the potential range -0.15–0.75 
V (vs. RHE) at a scan rate of 10 mV s
–1
 at room temperature. 
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